Sunday, December 12, 2021 11:35:30 AM
I am not a financial anything for anyone but myself and maybe some family. I am not a physician and do not practice anything licensed despite having a license in healthcare. I do not give anyone anywhere any permission to view this message and anyone referenced directly or indirectly by this and connected messages, as anything but private opinion and ASCO proves I can be wrong. I am not an attorney and while I may give my analysis of the law, I do not practice law and none of you are my clients in any way. I may or may not now work in the Biopharmaceutical industry, but do not give anyone permission to view that as me speaking on behalf of any company or regulator anywhere in the world. I am providing this as an alias and claim artistic license and will draw from history and media for purposes of illustrations of my private opinion and this does include you tube and authors of great works. I may be adapting concepts but I am not speaking on behalf of anyone and endorse no one at this moment but family and very close firends.
The full page advertisement to physicians reads disease, mechanism and registered trademarked brand name. Some or all of these are missing from previous endeavors with exception of scientific session. I did not walk the booth, see any full renditions, speak to anyone there or much else related. FDA has been lenient there anyway, but for only so long and deep. ASCO 2019 is different it is on Youtube or was for a long time. They removed the booth.
So yes, I believe those two bags and scenarios are dramatically different. Perhaps, I am wrong or FDA or some other regulators need more time.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
